Concept Life Sciences, a contract research organisation (CRO) serving the global life sciences industry, announces a strategic partnership with Edinburgh-based Fios Genomics, a bioinformatics provider serving clients globally.
The partnership will enable Concept Life Sciences to offer enhanced bioinformatics capabilities, empowering clients with deeper insights for more informed decision making throughout drug discovery and development.
This enhances Concept Life Sciences’ ability to meet the evolving needs of the global life sciences industry.
Fios Genomics is a bioinformatics company that transforms complex biological data into actionable insights with particular expertise in precision medicine.
Concept Life Sciences has exceptional capabilities and tools to generate data-rich readouts and has a long history of collaborating with clients to provide data interpretation and insight beyond the data.
Accessing advanced bioinformatics capabilities from Fios Genomics enables Concept Life Sciences to offer its clients richer data analysis in applications such as transcriptomics and high-content imaging, supporting faster, more confident decision making in research and development.
Hayley Gooding, Biology Services Director at Concept Life Sciences, commented: “This latest partnership underlines Concept Life Sciences’s growth strategy, further strengthening our ability to successfully accelerate drug candidates to clinic across different modalities and therapy areas."
"We are committed to delivering high-quality, integrated services to the global biopharmaceutical community. Together with Fios Genomics, a premier bioinformatics partner, we are poised to drive more effective and efficient outcomes in drug discovery and clinical development.”
“We are delighted to announce our new strategic alliance with Concept Life Sciences, our neighbour at Edinburgh BioQuarter."
"By combining their extensive experimental expertise with our advanced bioinformatics and statistical analysis capabilities, we can deliver integrated, end-to-end concept-to-clinic solutions."
"Together, we aim to support more researchers in making robust, data-driven decisions that accelerate and strengthen their programmes. We also see this partnership as an important milestone for Scotland’s life sciences sector, strengthening our collective offering to the global market,” added Sarah Lynagh, CEO of Fios Genomics.
The partnership also supports a diverse range of modalities beyond pharmaceutical drug discovery, providing valuable applications in agriculture, environmental science and veterinary research.